Satoreotide trizoxetan 5-20μg + Satoreotide trizoxetan 30-45μg

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gastro-Enteropancreatic Neuroendocrine Tumor

Conditions

Gastro-Enteropancreatic Neuroendocrine Tumor

Trial Timeline

Sep 26, 2017 → Aug 5, 2019

NCT ID

NCT03220217

About Satoreotide trizoxetan 5-20μg + Satoreotide trizoxetan 30-45μg

Satoreotide trizoxetan 5-20μg + Satoreotide trizoxetan 30-45μg is a phase 2 stage product being developed by Ipsen for Gastro-Enteropancreatic Neuroendocrine Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT03220217. Target conditions include Gastro-Enteropancreatic Neuroendocrine Tumor.

What happened to similar drugs?

1 of 1 similar drugs in Gastro-Enteropancreatic Neuroendocrine Tumor were approved

Approved (1) Terminated (1) Active (0)

✅Pasireotide + DiazoxideNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03220217	Phase 2	Completed	Sep 26, 2017	Aug 5, 2019	Gastro-Enteropancreatic Neuroendocrine Tumor

Competing Products

1 competing product in Gastro-Enteropancreatic Neuroendocrine Tumor

See all competitors

Product	Company	Stage	Hype Score
Pasireotide + Diazoxide	Novartis	Approved	35